Search results
PATHWAY-2 is the first randomised controlled trial to compare spironolactone with other blood pressure-lowering drug treatments in a well-characterised population of patients with resistant hypertension.
11 kwi 2018 · In the main PATHWAY-2 trial, after a 4-week single-blind placebo run-in, patients rotated through four cycles of once-daily oral treatment with spironolactone 25–50 mg, doxazosin 4–8 mg, bisoprolol 5–10 mg, and placebo, each for 12 weeks with forced titration to the higher dose after 6 weeks.
30 paź 2023 · Pathway. The pathway of the accessory nerve can be subdivided into several components. The nerve has an intracranialcourse, a brief passage through a foramen, and an extracranialcourse. The extracranial course can be further subdivided into the course in the anterior, and then in the posterior, triangles of the neck.
7 lis 2022 · In this multicenter, placebo-controlled trial, we randomly assigned patients who had treatment-resistant hypertension, with blood pressure of 130/80 mm Hg or higher, and who were receiving stable...
A phase Ib clinical trial of the C1-esterase inhibitor Cinryze, which inhibits the C1 complex of the antibody-initiated classical complement pathway, was safe in humans, with no adverse events (NCT01759602).
19 gru 2022 · Clinical evidence of accessory nerve injury has been observed to be 30% in selective neck dissections where cervical zones 2 through 4 and 5 were included. If zones 2 through 4 are dissected, and zone 5 is spared, this incidence decreases significantly.
17 lip 2023 · The accessory spinal nerve or XI cranial nerve is essential for neck and shoulder movement, the intrinsic musculature of the larynx, and the sensitive afferences of the trapezius and sternocleidomastoid musculature.
